China Cord Blood Corporation (CO) 5.36 $CO
China Cord Blood Corporation Files Its Annual Report on Form 20-F
PR Newswire - Thu Jul 28, 3:30PM CDT
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"
, China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The filed Form 20-F includes audited financial statements for the fiscal year ended March 31, 2016. The Form 20-F can be accessed by visiting the U.S. Securities and Exchange Commission's website at http://www.sec.gov and also be found at the Investor Relations section of CCBC's website at http://ir.chinacordbloodcorp.com. CCBC will provide a hard copy of the Annual Report, including a complete set of audited financial statements, free of charge to its shareholders upon request.
CO: 5.36 (+0.01)
China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2016
PR Newswire - Tue Jun 14, 3:16PM CDT
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company" , China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced its preliminary unaudited financial results for the fourth quarter and full year of the fiscal year 2016 ended March 31, 2016.
CO: 5.36 (+0.01)
China Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2016 Financial Results
PR Newswire - Tue Jun 07, 5:30AM CDT
China Cord Blood Corporation (NYSE: CO) (the "Company" today announced that it plans to release financial results for the fourth quarter and full year fiscal year 2016 on Tuesday, June 14, 2016, after market close.
CO: 5.36 (+0.01)
AmSurg Sees Balanced Growth amid Escalating Expenses
Zacks Equity Research - Zacks Investment Research - Fri Jan 08, 1:30PM CST
On Jan 6, 2015, we issued an updated research report on AmSurg Corporation (AMSG).
AMSG: 72.31 (+0.27), PMC: 26.46 (+0.39), CO: 5.36 (+0.01)
Golden Meditech Enters into Agreements with Nanjing Xinjiekou to Sell China Cord Blood Corporation
PR Newswire - Thu Jan 07, 7:03AM CST
Golden Meditech Holdings Limited (SEHK stock code: 801, TWSE stock code: 910801) ("Golden Meditech" or the "Company", together with its subsidiaries, the "Group" , a leading integrated healthcare enterprise in China, announces that it entered into a conditional sale and purchase agreement with Nanjing Xinjiekou Department Store Co., Ltd. (SSE stock code: 600682) ("Nanjing Xinjiekou" on 6 January 2016 regarding the disposal of its 65.4% equity interest (fully diluted) in China Cord Blood Corporation (NYSE stock code: CO) ("CCBC" for a total consideration of approximately RMB 5.76 billion.
CO: 5.36 (+0.01)
BUYINS.NET: STO, BPT, UTIW, ARI, CO, PRXL Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Dec 10, 5:58AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Statoil ASA (NYSE:STO), BP Prudhoe Bay Royalty Trust (NYSE:BPT), UTI WORLDWIDE INC (NASDAQ:UTIW), Apollo Commercial Real Estate Finance Inc (NYSE:ARI), China Cord Blood Corp (NYSE:CO), PAREXEL International Corp (NASDAQ
RXL) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
UTIW: 7.11 (+0.02), PRXL: 66.32 (-0.15), ARI: 16.13 (+0.06), BPT: 16.04 (+0.14), CO: 5.36 (+0.01), STO: 15.78 (+0.38)
China Cord Blood posts 2Q profit
Automated Insights - Mon Nov 23, 3:32PM CST
HONG KONG (AP) _ China Cord Blood Corp. (CO) on Monday reported fiscal second-quarter earnings of $2.9 million.
CO: 5.36 (+0.01)
China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2016
PR Newswire - Mon Nov 23, 3:16PM CST
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company" , China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced its preliminary unaudited financial results for the second quarter and first half of fiscal year 2016 ended September 30, 2015.
CO: 5.36 (+0.01)
China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2016 Financial Results
PR Newswire - Mon Nov 16, 5:00AM CST
China Cord Blood Corporation (NYSE: CO) (the "Company" today announced that it plans to release financial results for the second quarter and first half of fiscal year 2016 on Monday, November 23, 2015, after market close.
CO: 5.36 (+0.01)
China Cord Blood Corporation Guangdong Subsidiary Has Been Accredited by American Association of Blood Banks
PR Newswire - Fri Oct 30, 6:00AM CDT
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company" , China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company's Guangdong subsidiary, Guangdong Cord Blood Bank, was accredited by American Association of Blood Banks (AABB) in October 2015.
CO: 5.36 (+0.01)
China Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 10, 2015
PR Newswire - Wed Sep 23, 6:00AM CDT
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company" , China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company will hold its 2015 annual general meeting of shareholders at its Hong Kong office at 48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong, at 9:00 p.m. Hong Kong Time on December 10, 2015 (8:00 a.m. U.S. Eastern Standard Time on December 10, 2015).
CO: 5.36 (+0.01)
September 9, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital
PR Newswire - Wed Sep 09, 12:28PM CDT
The following is an open letter sent September 9, 2015 to the Board of Directors of China Cord Blood Corp (NYSE: CO) from Jayhawk Capital.
CBPO: 120.55 (+0.67), CO: 5.36 (+0.01)
China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2016
PR Newswire - Wed Aug 19, 3:05PM CDT
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company" , China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its preliminary unaudited financial results for the first quarter of fiscal 2016 ended June 30, 2015.
CO: 5.36 (+0.01)
ChinaCord (CO) at 52-Week High on Fresh Takeover Proposal
Zacks Equity Research - Zacks Investment Research - Mon Aug 17, 1:10PM CDT
As part of the proposal, Nanjing Xinjiekou also wishes to acquire all of China Cord's (CO) equity stakes in its Chinese subsidiaries.
AMSG: 72.31 (+0.27), AAC: 19.96 (-1.30), CO: 5.36 (+0.01), AMED: 51.08 (-2.70)
China Cord Blood Corporation to Report First Quarter of Fiscal 2016 Financial Results
PR Newswire - Thu Aug 13, 6:00AM CDT
China Cord Blood Corporation (NYSE: CO) (the "Company" today announced that it plans to release financial results for the first quarter of fiscal year 2016 on Wednesday, August 19, 2015, after market close.
CO: 5.36 (+0.01)
China Cord Blood (CO) Enters Overbought Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 10, 8:22AM CDT
China Cord Blood (CO) Enters Overbought Territory
CO: 5.36 (+0.01)
China Cord Blood (CO) in Focus: Stock Moves 13.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 07, 8:25AM CDT
China Cord Blood (CO) was a big mover last session, with shares rising nearly 14% on the day.
CO: 5.36 (+0.01), AMED: 51.08 (-2.70)
China Cord Blood receives non-binding acquisition proposal from Nanjing Xinjiekou Department Store Co
M2 - Fri Aug 07, 6:37AM CDT
China Cord Blood Corporation (NYSE:CO) said on Thursday that its board of directors has received a non-binding acquisition proposal letter to acquire all of its China business, including all of the equity interests in its China subsidiaries and its assets and resources relating to its business in China (the proposal).
CO: 5.36 (+0.01)
China Cord Blood Corporation Announces Receipt of Non-Binding Acquisition Proposal
PR Newswire - Thu Aug 06, 6:00AM CDT
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company" , China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that its board of directors has received a non-binding acquisition proposal letter from Nanjing Xinjiekou Department Store Co., Ltd. (the "Potential Acquirer" , pursuant to which the Potential Acquirer offered to acquire all the Company's China business, including all of the Company's equity interests in its China subsidiaries and its assets and resources relating to its business in China (the "Proposal" . The purchase price offered is not lower than RMB6.0 billion, to be paid in cash or shares or a combination thereof.
CO: 5.36 (+0.01)
China Cord Blood Corporation Files Its Annual Report on Form 20-F
PR Newswire - Thu Jul 28, 3:30PM CDT
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"
, China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The filed Form 20-F includes audited financial statements for the fiscal year ended March 31, 2016. The Form 20-F can be accessed by visiting the U.S. Securities and Exchange Commission's website at http://www.sec.gov and also be found at the Investor Relations section of CCBC's website at http://ir.chinacordbloodcorp.com. CCBC will provide a hard copy of the Annual Report, including a complete set of audited financial statements, free of charge to its shareholders upon request. CO: 5.36 (+0.01)
China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2016
PR Newswire - Tue Jun 14, 3:16PM CDT
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"
, China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced its preliminary unaudited financial results for the fourth quarter and full year of the fiscal year 2016 ended March 31, 2016. CO: 5.36 (+0.01)
China Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2016 Financial Results
PR Newswire - Tue Jun 07, 5:30AM CDT
China Cord Blood Corporation (NYSE: CO) (the "Company"
today announced that it plans to release financial results for the fourth quarter and full year fiscal year 2016 on Tuesday, June 14, 2016, after market close. CO: 5.36 (+0.01)
AmSurg Sees Balanced Growth amid Escalating Expenses
Zacks Equity Research - Zacks Investment Research - Fri Jan 08, 1:30PM CST
On Jan 6, 2015, we issued an updated research report on AmSurg Corporation (AMSG).
AMSG: 72.31 (+0.27), PMC: 26.46 (+0.39), CO: 5.36 (+0.01)
Golden Meditech Enters into Agreements with Nanjing Xinjiekou to Sell China Cord Blood Corporation
PR Newswire - Thu Jan 07, 7:03AM CST
Golden Meditech Holdings Limited (SEHK stock code: 801, TWSE stock code: 910801) ("Golden Meditech" or the "Company", together with its subsidiaries, the "Group"
, a leading integrated healthcare enterprise in China, announces that it entered into a conditional sale and purchase agreement with Nanjing Xinjiekou Department Store Co., Ltd. (SSE stock code: 600682) ("Nanjing Xinjiekou" on 6 January 2016 regarding the disposal of its 65.4% equity interest (fully diluted) in China Cord Blood Corporation (NYSE stock code: CO) ("CCBC" for a total consideration of approximately RMB 5.76 billion. CO: 5.36 (+0.01)
BUYINS.NET: STO, BPT, UTIW, ARI, CO, PRXL Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Dec 10, 5:58AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Statoil ASA (NYSE:STO), BP Prudhoe Bay Royalty Trust (NYSE:BPT), UTI WORLDWIDE INC (NASDAQ:UTIW), Apollo Commercial Real Estate Finance Inc (NYSE:ARI), China Cord Blood Corp (NYSE:CO), PAREXEL International Corp (NASDAQ
RXL) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: UTIW: 7.11 (+0.02), PRXL: 66.32 (-0.15), ARI: 16.13 (+0.06), BPT: 16.04 (+0.14), CO: 5.36 (+0.01), STO: 15.78 (+0.38)
China Cord Blood posts 2Q profit
Automated Insights - Mon Nov 23, 3:32PM CST
HONG KONG (AP) _ China Cord Blood Corp. (CO) on Monday reported fiscal second-quarter earnings of $2.9 million.
CO: 5.36 (+0.01)
China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2016
PR Newswire - Mon Nov 23, 3:16PM CST
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"
, China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced its preliminary unaudited financial results for the second quarter and first half of fiscal year 2016 ended September 30, 2015. CO: 5.36 (+0.01)
China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2016 Financial Results
PR Newswire - Mon Nov 16, 5:00AM CST
China Cord Blood Corporation (NYSE: CO) (the "Company"
today announced that it plans to release financial results for the second quarter and first half of fiscal year 2016 on Monday, November 23, 2015, after market close. CO: 5.36 (+0.01)
China Cord Blood Corporation Guangdong Subsidiary Has Been Accredited by American Association of Blood Banks
PR Newswire - Fri Oct 30, 6:00AM CDT
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"
, China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company's Guangdong subsidiary, Guangdong Cord Blood Bank, was accredited by American Association of Blood Banks (AABB) in October 2015. CO: 5.36 (+0.01)
China Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 10, 2015
PR Newswire - Wed Sep 23, 6:00AM CDT
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"
, China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company will hold its 2015 annual general meeting of shareholders at its Hong Kong office at 48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong, at 9:00 p.m. Hong Kong Time on December 10, 2015 (8:00 a.m. U.S. Eastern Standard Time on December 10, 2015). CO: 5.36 (+0.01)
September 9, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital
PR Newswire - Wed Sep 09, 12:28PM CDT
The following is an open letter sent September 9, 2015 to the Board of Directors of China Cord Blood Corp (NYSE: CO) from Jayhawk Capital.
CBPO: 120.55 (+0.67), CO: 5.36 (+0.01)
China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2016
PR Newswire - Wed Aug 19, 3:05PM CDT
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"
, China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its preliminary unaudited financial results for the first quarter of fiscal 2016 ended June 30, 2015. CO: 5.36 (+0.01)
ChinaCord (CO) at 52-Week High on Fresh Takeover Proposal
Zacks Equity Research - Zacks Investment Research - Mon Aug 17, 1:10PM CDT
As part of the proposal, Nanjing Xinjiekou also wishes to acquire all of China Cord's (CO) equity stakes in its Chinese subsidiaries.
AMSG: 72.31 (+0.27), AAC: 19.96 (-1.30), CO: 5.36 (+0.01), AMED: 51.08 (-2.70)
China Cord Blood Corporation to Report First Quarter of Fiscal 2016 Financial Results
PR Newswire - Thu Aug 13, 6:00AM CDT
China Cord Blood Corporation (NYSE: CO) (the "Company"
today announced that it plans to release financial results for the first quarter of fiscal year 2016 on Wednesday, August 19, 2015, after market close. CO: 5.36 (+0.01)
China Cord Blood (CO) Enters Overbought Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 10, 8:22AM CDT
China Cord Blood (CO) Enters Overbought Territory
CO: 5.36 (+0.01)
China Cord Blood (CO) in Focus: Stock Moves 13.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 07, 8:25AM CDT
China Cord Blood (CO) was a big mover last session, with shares rising nearly 14% on the day.
CO: 5.36 (+0.01), AMED: 51.08 (-2.70)
China Cord Blood receives non-binding acquisition proposal from Nanjing Xinjiekou Department Store Co
M2 - Fri Aug 07, 6:37AM CDT
China Cord Blood Corporation (NYSE:CO) said on Thursday that its board of directors has received a non-binding acquisition proposal letter to acquire all of its China business, including all of the equity interests in its China subsidiaries and its assets and resources relating to its business in China (the proposal).
CO: 5.36 (+0.01)
China Cord Blood Corporation Announces Receipt of Non-Binding Acquisition Proposal
PR Newswire - Thu Aug 06, 6:00AM CDT
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"
, China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that its board of directors has received a non-binding acquisition proposal letter from Nanjing Xinjiekou Department Store Co., Ltd. (the "Potential Acquirer" , pursuant to which the Potential Acquirer offered to acquire all the Company's China business, including all of the Company's equity interests in its China subsidiaries and its assets and resources relating to its business in China (the "Proposal" . The purchase price offered is not lower than RMB6.0 billion, to be paid in cash or shares or a combination thereof. CO: 5.36 (+0.01)
